NVCR stock sentiment todayNovoCure Limited
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
NVCR
NovoCure LimitedA binary-outcome medtech play stuck between disappointing clinical data and high-stakes FDA expansion potential.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for NVCR. Not financial advice.
Price · last 12 months
Gossip
The narrative is currently dominated by the polarizing results of the LUNAR trial and the upcoming FDA decision for non-small cell lung cancer (NSCLC). Bulls are betting on market expansion, while bears point to the underwhelming survival benefit and low physician adoption rates of the proprietary TTFields therapy.
- ·FDA approval decision for NSCLC expected in late 2024
- ·Skepticism over the clinical utility of Tumor Treating Fields (TTFields)
- ·High short interest and volatility following the LUNAR trial readout
Financial
NovoCure maintains a significant cash runway but continues to burn through capital as R&D and SG&A expenses outpace revenue growth in their core Glioblastoma (GBM) market, which has largely plateaued.
- ·Negative EPS with no clear path to profitability in the next 12-18 months
- ·Strong cash position (~$900M) providing buffer against short-term insolvency
- ·Gross margins remain high (>75%), but operating losses remain wide
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Regulatory rejection or restrictive labeling for the lung cancer indication
- ·Continued saturation and slow growth in the primary GBM market
- ·Heavy dilution risk if further capital raises are needed to fund commercial launches
Peer temperature
How direct competitors stack up against NVCR right now.
- HOTZLABZai Lab Limited
HOTTER — offers diversified revenue streams beyond TTFields and better exposure to the rapid Chinese oncology market.
See full analysis → - NEUTRALILMNIllumina, Inc.
SIMILAR — facing comparable growth stagnation and regulatory hurdles, though with a more dominant market-leading platform.
See full analysis → - HOTEXASExact Sciences Corp
HOTTER — demonstrating superior revenue scaling and a more established path toward consistent positive free cash flow.
See full analysis →
- NVCR-17.6%
- ZLAB-16.2%
- ILMN-13.8%
- EXAS—
Analyst price target
Consensus average of 6 analysts · median 20.00
Source: StockAnalysis.com · updated 2026-10-30
AI-generated analysis for informational purposes only. Not financial advice.